REG - Diaceutics PLC - Diaceutics - Capital Markets Event

DiaceuticsAnnouncement

14/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240514:nRSN2248Oa&default-theme=true

RNS Number : 2248O  Diaceutics PLC  14 May 2024

Diaceutics - Capital Markets Event - Wednesday, 12 June 2024

 

Belfast and London, 14 May 2024 - Diaceutics PLC (https://www.diaceutics.com/)
(AIM: DXRX), a leading technology and solutions provider to the pharma and
biotech industry, will host a virtual Capital Markets Event for analysts and
investors on Wednesday, 12 June 2024 at 1400-1600 BST (0900-1100 ET).

 

The event will include presentations from senior Diaceutics managers and
partners. The purpose of the event will be to give analysts and investors a
deeper insight into the DXRX platform, its functionality and hear from
partners as to how they use the platform to find patients.

 

Those wishing to attend can register using the following link:

 

https://us02web.zoom.us/webinar/register/WN_WNsaZ-s8SfauitOYaWjdLA
(https://us02web.zoom.us/webinar/register/WN_WNsaZ-s8SfauitOYaWjdLA)

 

Enquiries:

 

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almastrategic.com

 Kinvara Verdon

 Kieran Breheny

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEADSDFLXLEFA